PURE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PURE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PURE Bioscience's Enterprise Value is $9.54 Mil. PURE Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jul. 2024 was $-2.53 Mil. Therefore, PURE Bioscience's EV-to-FCF for today is -3.77.
The historical rank and industry rank for PURE Bioscience's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of PURE Bioscience was 249.69. The lowest was -89.25. And the median was -7.53.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-12), PURE Bioscience's stock price is $0.06758. PURE Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was $-0.030. Therefore, PURE Bioscience's PE Ratio (TTM) for today is At Loss.
The historical data trend for PURE Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience Annual Data | |||||||||||||||||||||
Trend | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | Jul24 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | 197.50 | -20.43 | -7.54 | -2.85 | -4.55 |
PURE Bioscience Quarterly Data | ||||||||||||||||||||
Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | |
EV-to-FCF | Get a 7-Day Free Trial | -2.85 | -3.36 | -5.03 | -3.75 | -4.55 |
For the Household & Personal Products subindustry, PURE Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's EV-to-FCF falls into.
PURE Bioscience's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 9.535 | / | -2.531 | |
= | -3.77 |
PURE Bioscience's current Enterprise Value is $9.54 Mil.
PURE Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (OTCPK:PURE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PURE Bioscience's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.06758 | / | -0.030 | |
= | At Loss |
PURE Bioscience's share price for today is $0.06758.
PURE Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of PURE Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert F Bartlett | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Bernard Blotner | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Tom Y Lee | director | 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776 |
David Rendall | director | 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730 |
Kristin Taylor | director | 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128 |
Dale Okuno | director | 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103 |
Ivan Chen | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Thomas Richard Myers | officer: Chief Operating Officer | 1725 GILLESPIE WAY, EL CAJON CA 92130 |
Henry R. Lambert | director, officer: Chief Executive Officer | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Elisabeth Hagen | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
Janet Risi Field | director | 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156 |
Franchise Brands, Llc | 10 percent owner | 325 BIC DRIVE, MILFORD CT 06461 |
Mark Stuart Elliott | officer: Vice President, Finance | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
William Otis | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
David M Theno | director | 1725 GILLESPIE WAY, EL CAJON CA 92020 |
From GuruFocus
By GuruFocus Research • 02-14-2024
By gurufocus 10qk • 03-17-2011
By [email protected] insider • 06-18-2020
By GuruFocus Research GuruFocus Editor • 12-28-2020
By GuruFocus Research • 02-14-2024
By [email protected] insider • 06-23-2020
By gurufocus 10qk • 12-15-2010
By PRNewswire PRNewswire • 11-02-2022
By gurufocus • 12-15-2008
By GuruFocus Research GuruFocus Editor • 06-30-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.